Editas Medicine (EDIT) Gets a Sell From Bank of America Securities
H.C. Wainwright Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $3
Express News | Editas Medicine Announces Five Abstracts At 28th Annual Meeting Of American Society Of Gene And Cell Therapy
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in Vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine Analyst Ratings
HC Wainwright Initiates Coverage on Editas Medicine With Buy Rating, $3 Price Target
Express News | Editas Medicine, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $3
$EDIT Stock Is up 12% Today. Here's What We See in Our Data.
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 59%
Dyne Therapeutics Names Editas Medicine's Lucera as CFO
Editas Medicine: Amy Parison to Succeed Lucera
Press Release: Editas Medicine Announces Chief Financial Officer Transition
Express News | Editas Medicine Announces Chief Financial Officer Transition
JonesTrading Maintains Editas Medicine(EDIT.US) With Hold Rating
Cautious Hold Rating on Editas Medicine Amid Early Development Stage and Long-Term Milestones
BofA Securities Maintains Editas Medicine(EDIT.US) With Sell Rating, Maintains Target Price $1
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $1 to $5
Sell Rating for Editas Medicine Amid Strategic Shift and Competitive Pressures
Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position
Editas Medicine (EDIT) Gets a Buy From Evercore ISI